Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of SHR-1701 in recurrent or metastatic advanced head and neck squamous cell carcinoma
CTR20202471Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Dec 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in head and neck squamous cell carcinoma (HNSCC), sponsored by Hengrui Therapeutics. Started Dec 2020; status: active.
02
Drugs
retlirafusp alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on CTR20202471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202471.